Description
| Description | ZZL-7 is a fast-onset antidepressant agent. ZZL-7 disrupts the interaction between the neuronal nitric oxide synthase (nNOS) and serotonin transporter (SERT) in the dorsal raphe nucleus (DRN). ZZL-7 can easily cross the blood-brain barrier readily. ZZL-7 has research value in major depressive disorder (MDD). |
| In vitro | In 293T cells transfected with nNOS and SERT, ZZL-7 (1.0 μM; 2 h) significantly decreases the SERT-nNOS complex level[1]. |
| In vivo | ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment. ZZL-7 (10, 20, and 40 mg/kg; Intragastric administration; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment. ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time[1]. |
| Molecular Weight |
244.29 |
| Formula | C11H20N2O4 |
| CAS No. | 99141-91-0 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 12 mg/mL (49.12 mM)
